Controlling Drug Release Through Osmotic Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Controlling Drug Release Through Osmotic Systems
Osmotic systems offer versatility for delivering drugs with varied properties and dosage requirements.


Pharmaceutical Technology
Volume 37, Issue 7, pp. 40-44

References
1. S.I. Shen, B.R. Jasti and X. Li, "Design of Controlled Release Drug Delivery Systems," in Standard Handbook of Biomedical Engineering & Design, M Kutz Ed. (McGraw-Hill, New York, 2003), pp. 221-235.

2. N. Basta, Pharmaceutical Commerce website, "Drug Delivery Technologies for Controlled Release Score with Manufacturers," http://pharmaceuticalcommerce.com/, accessed May 31, 2013.

3. R.K. Verma, D.M. Krishna and S. Garg, J, Control. Rel. 79 (1-3) 7-27 (2002).

4. D. Bhowmik et al., Pharma Innov. 1 (10) 24-32 (2012).

5 A. Nokhodchi et al., BioImpacts 2 (4) 175-187 (2012).

6. R.A. Siegel and M.J. Rathbone, "Overview of Controlled Release Mechanisms," in Fundamentals and Applications of Controlled Release Drug Delivery, J. Siepmann, R.A. Siegel and M.J. Rathbone Eds. (Springer, New York, 2012), pp. 19-43.

7. A. Bhargava et al., Int. J Adv. Res. Pharm. Biosci. 3 (1) 7-14 (2013).

8. A. Gauniya (2007), Pharmainfo website, "A Review on Latest Advancement in Patented Controlled/Sustained Release Drug Delivery System," http://www.pharmainfo.net/, accessed May 31, 2013.

9. D. Barbieri and E. Tocce, "Optimizing Controlled Release: The Use of Osmotic Oral Delivery Systems," Pharm. Technol. webcast, Sept. 19, 2012.

10. S. Pundir et al., Int. J Drug Res. Technol. 3 (1) 12-20 (2013).

11. P.M. Dandagi et al., Int. J Res. Pharm. Sci. 2 (2) 225-236 (2011).

12. N. Ahuja, V. Kumar and P. Rathee, Pharma Innov. 1 (7) 116-124 (2012).

13. H.M. Prajapati, S.T. Prajapati and C.N. Patel, Int. J. Pharmaceut. Res. Biosci. 1 (3) 158-194 (2012).

14. H. Patel et al., Int. Res. J Pharm. 3 (4) 88-94 (2012).

15. F. Theeuwes, J. Pharm. Sci. 64 (12) 1987-1991 (1975).

16. F. Theeuwes, "Osmotic System for Delivering Selected Beneficial Agents Having Varying Degrees of Solubility," US Patent 4111201 (Sept 1978).

17. R. Cortese and F. Theeuwes, "Osmotic Device with Hydrogel Driving Member,: US Patent 4327725 (May 1982).

18. G.M. Zentner, G.S. Rork, and K.J. Himmelstein, J. Control. Rel. 1 (4) 269-282 (1985).

19. G.M. Zentner, G.S. Rork and K.J. Himmelstein, "Controlled Porosity Osmotic Pump," European Patent 0169105 B1 (Aug 1991).

20. A.G. Thombre, G.M. Zentner, K.J. Himmelstein, J. Membr. Sci. 40 (3) 279-310 (1989).

21. A.G. Thombre et al., J. Control. Rel. 94 (1) 75-89 (2004).

22. G.M. Zentner, G. A. McClelland and S.C. Sutton, J. Control. Rel. 16 (1-2) 237-244 (1991).

23. S.M. Herbig et al., J. Control. Rel. 35 (2-3) 127-136 (1995).

24. A.K. Philip and K. Pathak, AAPS PharmSciTech 7 (3) 1-11 (2006).

25. A.K. Philip and B. Philip, PDA J. Pharm. Sci. Technol. 65(1) 32-41 (2011).

26. A.G. Thombre et al., J. Control. Rel. 57 (1) 65-73 (1999).

27. A.G. Thombre et al., J. Control. Rel. 57 (1) 55-64 (1999).

28. L. Kumar et al., Int. J. Pharm. Pharmaceut. Sci. 4 (2) 54-59 (2012).

29. N. G. Gobade, M. Koland and K. H. Harish, Indian J. Pharm. Sci. 74 (1) 69-72 (2012).

30. A.K. Philip and K. Pathak, Indian J. Pharm. Sci. 70 (6) 745-753 (2008).

31. A.K. Philip, K. Pathak, and P. Shakya, Eur. J. Pharm. Biopharm. 69 (2) 658-666 (2008).

32. S. Garg et al., Sci. Pharm. 80 (1) 229-250 (2012).

33. J. Guan et al., Pharm. Res. 27 (1) 105-114 (2010).

34. M.S. Chauhan, A. Kumar and K. Pathak, AAPS PharmSciTech 13 (4) 1492-1501 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here